Lauren K. Brady
Research Subjects
Lauren K. Brady has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Brandon W. Higgs
Translational Data Science, Genmab, Princeton, NJ
21 shared publications - Maria Jure-Kunkel
Translational Research and Precision Medicine Operations, Genmab, Princeton, NJ
21 shared publications - Andrew William Chen
24Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
17 shared publications - Christian U. Blank
Leiden University Medical Center, Leiden, The Netherlands
17 shared publications Cristopher Lao
17 shared publications- Despina Kontos
Department of Radiology, Columbia University, 622 W. 168th St, Alianza Dominicana Cultural Center, 5th Fl, New York, NY 10032
17 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated with Clinical Activity
Purpose:Tisotumab vedotin (TV) is a tissue factor (TF)–specific antibody–drug conjugate (ADC) that was evaluated in the innovaTV 204 study in patients with recurrent or metastatic cervical cancer (r/mCC). Although TF expression is required for TV binding to tumor cells, clinical responses were found to be independent of TF levels. This study aimed to evaluate whether baseline tumor gene expression signatures consistent with the proposed mechanisms of action of TV were associated with clinical outcomes. Experimental Design:Pretreatment tumor samples from patients enrolled in innovaTV 204 (NCT03438396), a phase II, single-arm, multicenter trial of TV in r/mCC following chemotherapy, were profiled for molecular biomarkers. Gene expression analyses of immune-related signatures were stratified by clinical response. In vitro antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) assays were performed using tumor cell lines with variable TF expression. Results:TF expression was confirmed in most patients but did not associate with response. Higher expression of gene signatures linked to natural killer (NK) cells and myeloid cells was associated with improved clinical outcomes. In vitro, TV induced tumor cell death through myeloid-mediated ADCP and NK-mediated ADCC across various TF expression levels. Conclusions:This work provides supportive evidence for TV mechanisms of action that involve antitumor effects through direct cytotoxic and immune effector–mediated mechanisms. The association of immune-related gene signatures with improved clinical outcomes supports a multimodal mechanism of action for TV in the clinic and provides further rationale for ADC efficacy in tumors with heterogeneous target expression.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated with Clinical Activity
Purpose:Tisotumab vedotin (TV) is a tissue factor (TF)–specific antibody–drug conjugate (ADC) that was evaluated in the innovaTV 204 study in patients with recurrent or metastatic cervical cancer (r/mCC). Although TF expression is required for TV binding to tumor cells, clinical responses were found to be independent of TF levels. This study aimed to evaluate whether baseline tumor gene expression signatures consistent with the proposed mechanisms of action of TV were associated with clinical outcomes. Experimental Design:Pretreatment tumor samples from patients enrolled in innovaTV 204 (NCT03438396), a phase II, single-arm, multicenter trial of TV in r/mCC following chemotherapy, were profiled for molecular biomarkers. Gene expression analyses of immune-related signatures were stratified by clinical response. In vitro antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) assays were performed using tumor cell lines with variable TF expression. Results:TF expression was confirmed in most patients but did not associate with response. Higher expression of gene signatures linked to natural killer (NK) cells and myeloid cells was associated with improved clinical outcomes. In vitro, TV induced tumor cell death through myeloid-mediated ADCP and NK-mediated ADCC across various TF expression levels. Conclusions:This work provides supportive evidence for TV mechanisms of action that involve antitumor effects through direct cytotoxic and immune effector–mediated mechanisms. The association of immune-related gene signatures with improved clinical outcomes supports a multimodal mechanism of action for TV in the clinic and provides further rationale for ADC efficacy in tumors with heterogeneous target expression.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4365-4373
Molecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated with Clinical Activity
Purpose: Tisotumab vedotin (TV) is a tissue factor (TF)–specific antibody–drug conjugate (ADC) that was evaluated in the innovaTV 204 study in patients with recurrent or metastatic cervical cancer (r/mCC). Although TF expression is required for TV binding to tumor cells, clinical responses were found to be independent of TF levels. This study aimed to evaluate whether baseline tumor gene expression signatures consistent with the proposed mechanisms of action of TV were associated with clinical outcomes. Experimental Design: Pretreatment tumor samples from patients enrolled in innovaTV 204 (NCT03438396), a phase II, single-arm, multicenter trial of TV in r/mCC following chemotherapy, were profiled for molecular biomarkers. Gene expression analyses of immune-related signatures were stratified by clinical response. In vitro antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) assays were performed using tumor cell lines with variable TF expression. Results: TF expression was confirmed in most patients but did not associate with response. Higher expression of gene signatures linked to natural killer (NK) cells and myeloid cells was associated with improved clinical outcomes. In vitro, TV induced tumor cell death through myeloid-mediated ADCP and NK-mediated ADCC across various TF expression levels. Conclusions: This work provides supportive evidence for TV mechanisms of action that involve antitumor effects through direct cytotoxic and immune effector–mediated mechanisms. The association of immune-related gene signatures with improved clinical outcomes supports a multimodal mechanism of action for TV in the clinic and provides further rationale for ADC efficacy in tumors with heterogeneous target expression.
- 17 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4365-4373
Open AccessMolecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated with Clinical Activity
Purpose: Tisotumab vedotin (TV) is a tissue factor (TF)–specific antibody–drug conjugate (ADC) that was evaluated in the innovaTV 204 study in patients with recurrent or metastatic cervical cancer (r/mCC). Although TF expression is required for TV binding to tumor cells, clinical responses were found to be independent of TF levels. This study aimed to evaluate whether baseline tumor gene expression signatures consistent with the proposed mechanisms of action of TV were associated with clinical outcomes. Experimental Design: Pretreatment tumor samples from patients enrolled in innovaTV 204 (NCT03438396), a phase II, single-arm, multicenter trial of TV in r/mCC following chemotherapy, were profiled for molecular biomarkers. Gene expression analyses of immune-related signatures were stratified by clinical response. In vitro antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) assays were performed using tumor cell lines with variable TF expression. Results: TF expression was confirmed in most patients but did not associate with response. Higher expression of gene signatures linked to natural killer (NK) cells and myeloid cells was associated with improved clinical outcomes. In vitro, TV induced tumor cell death through myeloid-mediated ADCP and NK-mediated ADCC across various TF expression levels. Conclusions: This work provides supportive evidence for TV mechanisms of action that involve antitumor effects through direct cytotoxic and immune effector–mediated mechanisms. The association of immune-related gene signatures with improved clinical outcomes supports a multimodal mechanism of action for TV in the clinic and provides further rationale for ADC efficacy in tumors with heterogeneous target expression.
- Open Access
- 23 May 2026
- Published by Elsevier in Translational Oncology
- Vol. 70, 102822
Integrated histopathology–transcriptomic biomarker enhances survival prediction in HNSCC patients treated with immunotherapy
- 23 May 2026
- Published by Elsevier in Translational Oncology
- Vol. 70, 102822
Open AccessIntegrated histopathology–transcriptomic biomarker enhances survival prediction in HNSCC patients treated with immunotherapy
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Demographics and baseline characteristics of patients in the dose-expansion population by cohort.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Demographics and baseline characteristics of patients in the dose-expansion population by cohort.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Safety summary: TEAEs in ≥5% of patients overall in dose-escalation phase (3Q4W schedule)
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Safety summary: TEAEs in ≥5% of patients overall in dose-escalation phase (3Q4W schedule)
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Safety summary: TEAEs in ≥20% of patients in any cohort in dose-expansion phase
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Safety summary: TEAEs in ≥20% of patients in any cohort in dose-expansion phase
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Best change from baseline in sum of target lesions (investigator assessment) in the dose-expansion phase for the NSCLC cohorts (A, C, and E) and baseline tumor H-score levels for AXL positivity by investigator-assessed confirmed best overall response (B, D, and F). A and B, Cohort 1 (Q3W): NSCLC with sensitizing EGFR mutations and/or mutations targeted by third-generation TKIs (n = 22). C and D, Cohort 2 (2.2 mg/kg Q3W): NSCLC without activating EGFR mutations or ALK rearrangements (n = 55). E and F, Cohort 8 (3Q4W): NSCLC without activating EGFR mutations or ALK rearrangements (n = 26). NE, not evaluable; PD, progressive disease; PR, partial response.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Best change from baseline in sum of target lesions (investigator assessment) in the dose-expansion phase for the NSCLC cohorts (A, C, and E) and baseline tumor H-score levels for AXL positivity by investigator-assessed confirmed best overall response (B, D, and F). A and B, Cohort 1 (Q3W): NSCLC with sensitizing EGFR mutations and/or mutations targeted by third-generation TKIs (n = 22). C and D, Cohort 2 (2.2 mg/kg Q3W): NSCLC without activating EGFR mutations or ALK rearrangements (n = 55). E and F, Cohort 8 (3Q4W): NSCLC without activating EGFR mutations or ALK rearrangements (n = 26). NE, not evaluable; PD, progressive disease; PR, partial response.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Safety summary: TEAEs in ≥5% of patients overall and grade ≥3 TEAEs in dose-escalation phase (Q3W schedule)
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Safety summary: TEAEs in ≥5% of patients overall and grade ≥3 TEAEs in dose-escalation phase (Q3W schedule)